Cargando…

Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014

OBJECTIVE: The objective of this study was to describe healthcare resource use and cost development in Sweden during 2006–2014 in a type 2 diabetes (T2D) population receiving glucose-lowering drugs (GLDs). METHODS: In- and outpatient healthcare resource use and costs were extracted from mandatory na...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nathanson, David, Sabale, Ugne, Eriksson, Jan W., Nyström, Thomas, Norhammar, Anna, Olsson, Urban, Bodegård, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249189/ https://www.ncbi.nlm.nih.gov/pubmed/29623637 http://dx.doi.org/10.1007/s41669-017-0063-y

Ejemplares similares

Dapagliflozin vs non‐SGLT‐2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
por: Nyström, Thomas, et al.
Publicado: (2017)

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study
por: Kristófi, Robin, et al.
Publicado: (2021)

Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data
por: Kristófi, Robin, et al.
Publicado: (2022)

History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks in Sweden: a registry-based, retrospective, case–control study
por: Ritsinger, Viveca, et al.
Publicado: (2023)

IDF2022-0622 Mortality and cardiorenal disease in type 1 and type 2 diabetes after COVID-19 and influenza hospitalization in Sweden
por: Kristófl, R., et al.
Publicado: (2023)

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
por: Persson, Frederik, et al.
Publicado: (2017)

Different patterns of second‐line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
por: Persson, Frederik, et al.
Publicado: (2018)

Nationwide trends in glucose-lowering drug use, Denmark, 1999–2014
por: Christensen, Diana Hedevang, et al.
Publicado: (2016)

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
por: Kosiborod, Mikhail, et al.
Publicado: (2017)

Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
por: Birkeland, Kåre I., et al.
Publicado: (2020)

Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
por: Norhammar, Anna, et al.
Publicado: (2022)

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
por: Kohsaka, Shun, et al.
Publicado: (2020)

No increase in new users of blood glucose-lowering drugs in Norway 2006–2011: a nationwide prescription database study
por: Strøm, Hanne, et al.
Publicado: (2014)

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
por: Norhammar, Anna, et al.
Publicado: (2023)

Incidence, Characteristics, and Cost of Eyelid Lacerations in the United States from 2006 to 2014
por: Cade, Keale L., et al.
Publicado: (2022)

Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry
por: Ritsinger, Viveca, et al.
Publicado: (2020)

Temporal trends in the initiation of glucose-lowering medications after a first-time myocardial infarction - a nationwide study between 1997 and 2006
por: Norgaard, Mette L, et al.
Publicado: (2011)

Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden
por: Sabale, Ugne, et al.
Publicado: (2017)

Impact assessment of immunization and the COVID-19 pandemic on varicella across Europe using digital epidemiology methods: A descriptive study
por: Sabale, Ugne, et al.
Publicado: (2023)

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study
por: Birkeland, Kåre I., et al.
Publicado: (2019)

Initiation and Persistence to Statin Treatment in Patients with Diabetes Receiving Glucose-Lowering Medications 1997- 2006
por: Dominguez, H., et al.
Publicado: (2009)

Turtle-Associated Salmonellosis, United States, 2006–2014
por: Bosch, Stacey, et al.
Publicado: (2016)

Imported Chikungunya Virus Strains, Taiwan, 2006–2014
por: Yang, Cheng-Fen, et al.
Publicado: (2016)

The Cost-Variation Index for 2006
Publicado: (2005)

Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study
por: Jernberg, Tomas, et al.
Publicado: (2019)

Economic Burden of Cervical Cancer in Bulgaria
por: Lebanova, Hristina, et al.
Publicado: (2023)

Effect of flash glucose monitoring in adults with type 1 diabetes: a nationwide, longitudinal observational study of 14,372 flash users compared with 7691 glucose sensor naive controls
por: Nathanson, David, et al.
Publicado: (2021)

Tuberculosis drug resistance in Bamako, Mali, from 2006 to 2014
por: Diarra, B., et al.
Publicado: (2016)

Travel-Related Tick-Borne Encephalitis, Israel, 2006–2014
por: Meltzer, Eyal, et al.
Publicado: (2017)

One-year survival rate and healthcare costs after cardiac arrest in Taiwan, 2006–2012
por: Weng, Yi-Ming, et al.
Publicado: (2018)

Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan
por: Chang, Hsien-Yen, et al.
Publicado: (2021)

Information on the Cost-Variation Index for 2006
Publicado: (2005)

Hemorrhagic Fever with Renal Syndrome, Zibo City, China, 2006–2014
por: Wang, Ling, et al.
Publicado: (2016)

Spatiotemporal Dynamics of Scrub Typhus Transmission in Mainland China, 2006-2014
por: Wu, Yi-Cheng, et al.
Publicado: (2016)

The Incidence and Mortality of Cervical Cancer in Ningbo during 2006–2014, China
por: LI, Hui, et al.
Publicado: (2017)

Predictors and Trend in Attendance for Breast Cancer Screening in Lithuania, 2006–2014
por: Kriaucioniene, Vilma, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fcssb5jtm9icmth00p0cg425p3